Research progress of PD?1/PD?L1 in prostate cancer immunotherapy.

Pro,state cancer is the .second most common cancer in men and the fifth leading cau.se of cancer deaths in men.Although there is an initial response to traditional treatments which include radical prostatectomy, chemotherapy, androgen deprivation therapy, and so on, some patients eventually progress to castration-resistant prostate cancer. The human immune system can perform a monitoring function to kill tumor cells promptly, however,tumor cells also express PD-L1 as they evolve, which binds to PD-1 on T cells and can inhibit T cell function, ultimately inducing immune evasion. The in-depth study of PD-1/PD-L1 in the mechanism of immune evasion in prostate cancer may provide new therapeutic strategies for the future application of PD-1/ PD-L1-based immunotherapy in prostate cancer treatment. In this paper, we will review the latest research progress of PD-1/ PD-L1 in prostate cancer immunotherapy. [ABSTRACT FROM AUTHOR]